11.2 Neurogenic Bladder & Bowel Management

ABPMR Physical Medicine and Rehabilitation Board Exam Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction & Exam Overview

1.1 ABPMR Part I Exam Overview & Format 1.2 Board Review Strategy & Content Blueprint Breakdown

2 Chapter 2: Musculoskeletal Medicine

2.1 Shoulder & Upper Extremity Diagnostics 2.2 Knee, Hip & Lower Extremity Conditions 2.3 Spine Pathology, Radiculopathy & Myelopathy 2.4 Inflammatory Arthritis, Tendinopathies & Concussion 2.5 Bone Health, Osteoporosis & Metabolic Bone Disease 2.6 Thoracic Outlet Syndrome & Peripheral Nerve Entrapment 2.7 Fracture Rehabilitation & Immobilization Complications 2.8 Overuse Tendinopathies & Regenerative Medicine 2.9 Gait Analysis & Abnormal Gait Patterns

3 Chapter 3: Spinal Cord Injury Rehabilitation

3.1 ASIA Examination & Impairment Scale 3.2 Spinal Cord Injury Syndromes 3.3 Autonomic Dysreflexia & Acute Complications 3.4 Neurogenic Bladder, Bowel & Secondary Complications

4 Chapter 4: Stroke & Neuromuscular Rehabilitation

4.1 Stroke Vascular Syndromes & Acute Assessment 4.2 Stroke Motor Recovery & Hemiplegic Complications 4.3 Spasticity Assessment & Multimodal Management 4.4 ALS, GBS, CIDP & Neuromuscular Disease Rehab 4.5 Multiple Sclerosis & Demyelinating Disease Rehabilitation 4.6 Parkinsonism, Movement Disorders & Functional Neurologic Disorder

5 Chapter 5: Electrodiagnostics (EMG/NCS)

5.1 Nerve Conduction Studies Principles & Physics 5.2 Needle Electromyography & MUAP Analysis 5.3 Mononeuropathies & Radiculopathy Patterns 5.4 Neuromuscular Junction Disorders & Myopathies

6 Chapter 6: Traumatic Brain Injury

6.1 TBI Severity Classification, Glasgow Coma Scale, and Pathophysiology 6.2 Rancho Los Amigos Levels of Cognitive Functioning and Disability Rating Scale 6.3 Neurobehavioral Sequelae and Agitation Management 6.4 Concussion Evaluation, Vestibular-Ocular Dysfunction, and Return-to-Play/Work Protocols

7 Chapter 7: Chronic Pain & Interventional Spine

7.1 Fluoroscopic Spine Interventions 7.2 Opioid Stewardship & Controlled Substance Compliance 7.3 Complex Regional Pain Syndrome, Fibromyalgia & Myofascial Pain 7.4 Spinal Cord Stimulation & Intrathecal Therapy

8 Chapter 8: Amputee Rehabilitation & Prosthetics

8.1 Amputation Surgical Levels & Medicare K-Levels 8.2 Socket Designs & Suspension Systems 8.3 Prosthetic Feet & Microprocessor Knee Mechanisms 8.4 Post-Amputation Care, Residual Limb & Phantom Pain

9 Chapter 9: Pediatric Rehabilitation

9.1 Cerebral Palsy Classification & GMFCS 9.2 Spina Bifida & Myelomeningocele Management 9.3 Muscular Dystrophies & Neuromuscular Disease in Children 9.4 Pediatric Brachial Plexopathy & Congenital Disorders

10 Chapter 10: Prosthetics, Orthotics & Assistive Technology

10.1 Lower Limb Orthoses — AFOs & KAFOs 10.2 Spinal & Upper Extremity Orthoses 10.3 Upper Limb Prosthetics — Body-Powered vs Myoelectric 10.4 Wheelchairs, Seating Systems & Pressure Mapping

11 Chapter 11: Medical Rehabilitation & Outcomes

11.1 Dysphagia Assessment & Management 11.2 Neurogenic Bladder & Bowel Management 11.3 Pressure Injuries & Wound Management 11.4 Outcome Measures & Medical Complications 11.5 Cancer Rehabilitation & Oncologic Rehabilitation 11.6 Burns, Endocrine/Metabolic & Medical Complications Rehabilitation

12 Chapter 12: Cardiopulmonary Rehabilitation

12.1 Cardiac Rehabilitation Phases & Metabolic Equivalents 12.2 Pulmonary Rehabilitation & COPD Management

13 Chapter 13: Foundational Rehabilitation Concepts

13.1 Kinesiology, Biomechanics & Functional Anatomy 13.2 Rehabilitation Pharmacology & Medication Management 13.3 Research Methodology, Biostatistics & Evidence-Based Practice 13.4 Nutrition, Metabolism & Energy Expenditure in Rehabilitation 13.5 Diagnostic Procedures: Imaging, MSK Ultrasound, Urodynamics & Neuropsych Assessment

11.2 Neurogenic Bladder & Bowel Management

Key Takeaways Explain This Topic AI

Suprasacral UMN spinal cord lesions cause Detrusor Hyperreflexia and Detrusor Sphincter Dyssynergia (DSD), producing high storage pressures (>40 cm H2O) and autonomic dysreflexia risk.

Sacral/LMN lesions cause Detrusor Areflexia (flaccid bladder) with high post-void residual volumes and overflow incontinence.

Clean Intermittent Catheterization (CIC) every 4 to 6 hours maintaining catheterized volumes <400-500 mL plus anticholinergics or beta-3 agonists is the gold standard bladder management.

UMN bowel (hyperreflexic) relies on digital rectal stimulation and suppositories with soft-formed stool, whereas LMN bowel (flaccid) requires manual evacuation and firm-formed stool.

Last updated: July 2026

Neurogenic Bladder Pathophysiology & Urodynamic Concepts

Neurogenic bladder dysfunction is categorized based on the level of neurological lesion relative to the major micturition control centers: the Pontine Micturition Center (PMC) , the Thoracolumbar Sympathetic Center (T11–L2) , and the Sacral Parasympathetic / Somatic Center (S2–S4) .

Suprasacral (Upper Motor Neuron - UMN) Lesions

Location : Spinal cord lesions above the sacral micturition center (above T12/L1 level).

Bladder Phenotype : Detrusor Hyperreflexia / Overactivity with or without Detrusor Sphincter Dyssynergia (DSD) .

Pathophysiology : Disruption of descending reticulospinal pathways isolates the sacral reflex arc from cortical and pontine inhibitory control. The detrusor muscle contracts involuntarily at low filling volumes.

Detrusor Sphincter Dyssynergia (DSD) : Involuntary, discoordinated contraction of the striated external urethral sphincter ( pudendal nerve, S2–S4 ) occurring simultaneously with detrusor contraction. DSD acts as a functional bladder outlet obstruction, generating markedly elevated intravesical pressures during micturition.

Complications : High storage and voiding pressures ( > 40 cm H 2 O >40\text{ cm H}_2\text{O} > 40 cm H 2 O ) can lead to vesicoureteral reflux (VUR) , hydronephrosis, renal scarring, pyelonephritis, and progressive renal failure. In lesions at or above T6 , DSD and bladder distension are classic triggers for autonomic dysreflexia (AD) .

Sacral and Infrasacral (Lower Motor Neuron - LMN) Lesions

Location : Lesions involving the sacral micturition center (conus medullaris, S2–S4), cauda equina, or peripheral pelvic nerves.

Bladder Phenotype : Detrusor Areflexia / Acontractility (flaccid bladder) with intact or impaired sphincter tone.

Pathophysiology : Interruption of the sacral parasympathetic reflex arc ( pelvic splanchnic nerves, S2–S4 ) abolishes detrusor contractility. The bladder fills passively to large capacities without sensation or contraction.

Complications : Markedly elevated post-void residual (PVR) volumes, chronic bladder overdistension, detrusor muscle overstretching, urinary tract infections (UTIs), and overflow incontinence .

Urodynamic Study (UDS) Parameters

Urodynamics is the definitive diagnostic modality for evaluating lower urinary tract function in rehabilitation:

Bladder Compliance ( Δ V / Δ P \Delta V / \Delta P Δ V /Δ P ) : Change in volume divided by change in detrusor pressure during filling. Normal compliance is > 30 mL/cm H 2 O >30\text{ mL/cm H}_2\text{O} > 30 mL/cm H 2 O . Low compliance ( < 10 – 12 mL/cm H 2 O <10\text{–}12\text{ mL/cm H}_2\text{O} < 10 – 12 mL/cm H 2 O ) reflects rigid, non-compliant bladder walls and high risk for upper tract deterioration.

Detrusor Leak Point Pressure (DLPP) : The lowest detrusor pressure at which urine leakage occurs around the catheter in the absence of abdominal straining or detrusor contraction. DLPP > 40 cm H 2 O >40\text{ cm H}_2\text{O} > 40 cm H 2 O is a critical risk threshold strongly correlated with upper urinary tract damage and hydronephrosis.

Maximum Cystometric Capacity (MCC) : The bladder volume at which the patient experiences an uncomfortable urge to void or at which filling is halted (normal adult MCC: 350–500 mL).

Clean Intermittent Catheterization (CIC)

Clean Intermittent Catheterization (CIC) is the gold standard for neurogenic bladder emptying in individuals with UMN or LMN neurogenic bladder who possess adequate hand function or have dedicated caregiver support.

Parameter Standard Clinical Guidelines & Best Practices

Catheterization Frequency Every 4 to 6 hours (q4–6h) while awake (typically 4–6 times daily).

Target Catheterized Volume Keep individual catheterized volumes < 400 – 500 mL <400\text{--}500\text{ mL} < 400 – 500 mL (ideally < 400 mL <400\text{ mL} < 400 mL ).

Fluid Intake Management Limit fluid intake to 1.5 – 2.0 L/day 1.5\text{--}2.0\text{ L/day} 1.5 – 2.0 L/day evenly distributed to prevent bladder overdistension between catheterizations.

Hygiene Technique Clean (non-sterile) technique using washcloth/soap and reusable or single-use catheters in community settings.

Complications Prevented Prevents detrusor overstretching, wall ischemia, high storage pressures, VUR, and autonomic dysreflexia.

Asymptomatic Bacteriuria Extremely common ( > 50 – 70 % >50\text{--}70\% > 50 – 70% ). Do NOT treat with antibiotics unless accompanied by systemic signs/symptoms.

Pharmacotherapy & Interventional Procedures for Neurogenic Bladder [Neurogenic Bladder Management Flowchart]
│
┌───────────────┴───────────────┐
▼ ▼
[Detrusor Overactivity (UMN)] [Detrusor Areflexia (LMN)]
│ │

First Line: First Line:

CIC q4-6h (Vol <400-500mL) • Timed CIC q4-6h
Anticholinergics (Oxybutynin) • Valsalva/Credé (Caution)
Beta-3 Agonist (Mirabegron) │

│ Refractory:

Refractory: • Alpha-blockers
Intravesical Botox 200U • Surgical Diversion

Anticholinergic / Antimuscarinic Medications :

Agents : Oxybutynin (oral/transdermal), Tolterodine , Solifenacin , Darifenacin .

Mechanism of Action : Competitive antagonist of muscarinic acetylcholine receptors ( M2 and M3 ) on detrusor smooth muscle. Inhibits uninhibited detrusor contractions, increases maximum cystometric capacity, and lowers storage pressures.

Side Effects : Dry mouth (xerostomia), constipation, blurred vision (mydriasis), tachycardia, urinary retention, and cognitive impairment / central nervous system effects (especially in elderly patients or those with TBI, mediated by crossing the blood-brain barrier).

Beta-3 Adrenergic Agonists :

Agents : Mirabegron , Vibegron .

Mechanism of Action : Selective agonist of beta-3 adrenergic receptors in detrusor muscle. Stimulates detrusor relaxation during the storage phase, enhancing bladder compliance and capacity without anticholinergic side effects .

Clinical Utility : Excellent alternative or add-on therapy for patients unable to tolerate antimuscarinics. Precaution : Mirabegron can elevate blood pressure; monitor in patients with uncontrolled hypertension.

Intravesical OnabotulinumtoxinA (Botox) :

Indication : Neurogenic detrusor overactivity refractory to oral pharmacotherapy.

Mechanism of Action : Injected cytoscopically into the detrusor muscle (typically 200 units across 20–30 sites, sparing the trigone). Botox cleaves SNAP-25 , inhibiting presynaptic acetylcholine release at the neuromuscular junction.

Efficacy & Duration : Reduces intravesical pressure and incontinence episodes for 6 to 9 months .

Adverse Effect : Transient urinary retention requiring CIC, and increased incidence of UTIs.

Neurogenic Bowel Management: UMN vs. LMN

Neurogenic bowel dysfunction following neurological injury is categorized into Upper Motor Neuron (UMN) bowel and Lower Motor Neuron (LMN) bowel based on the preservation of the sacral reflex arc ( S2–S4 ).

Clinical Feature Upper Motor Neuron (UMN) Bowel Lower Motor Neuron (LMN) Bowel

Lesion Location Above S2 (Spinal cord injury above T12/L1). At S2–S4 or Cauda Equina / Conus Medullaris.

Pathophysiology Hyperreflexic / Spastic bowel ; intact sacral reflex arc. Areflexic / Flaccid bowel ; lost sacral reflex arc.

Anal Sphincter Tone Hypertonic / spastic internal and external sphincters. Atonic / flaccid external sphincter and pelvic floor.

Transit Time & Stool Prolonged colonic transit; stool is dry and hard. Slow colonic transit; stool accumulates in rectum.

Primary Risk Severe constipation, impaction, autonomic dysreflexia. Fecal incontinence due to open, flaccid sphincter.

Bowel Program Focus Reflexive evacuation triggered by rectal stimulation. Manual evacuation and firm stool consistency.

Interventions Suppositories (Bisacodyl, Glycerin) + Digital Rectal Stimulation (DRS) . Manual digital evacuation , abdominal massage, gravity.

Target Stool Consistency Bristol Stool Scale Type 3–4 (soft, formed). Bristol Stool Scale Type 2–3 (firm, formed).

Pharmacological Bowel Regimen Agents

Stool Softeners : Docusate sodium (emulsifies water and fat into stool; ineffective as monotherapy).

Osmotic Laxatives : Polyethylene glycol (PEG 3350 / Miralax) , Lactulose , Magnesium hydroxide . Draws water into the bowel lumen to increase stool bulk and softness.

Stimulant Laxatives : Bisacodyl (oral or rectal suppository), Senna . Direct chemical stimulation of the myenteric plexus to induce colonic peristalsis. Rectal bisacodyl works within 15–30 minutes to initiate a UMN bowel program.

Prokinetics : Metoclopramide , Prucalopride (selective 5-HT4 agonist). Enhances gastrointestinal motility in severe slow-transit constipation.